Sign Up to like & get
recommendations!
1
Published in 2018 at "Gut"
DOI: 10.1136/gutjnl-2018-317735
Abstract: Recent FDA approval of anti-PD-1 antibody pembrolizumab as a site-agnostic therapy for mismatch repair (MMR)–deficient solid tumours has highlighted the importance of CD8+ T cell responses and the potential of immunotherapy, even in tumour entities that are…
read more here.
Keywords:
immunosuppressive links;
stroma dysfunctional;
dysfunctional cells;
tumour stroma ... See more keywords